Innoviva, Inc.

• 10-QQ2 FY2026Positive

  Filed Aug 5

  XACDURO and GIAPREZA growth outweighed declining GSK royalties; investment valuation losses swung GAAP earnings to a loss.

  • Revenue$119.6MYoY +19.3%
  • Net income−$83.4Mvs $63.7M year ago

• 8-KPositiveEarningsGuidance reaffirmed

  Filed Aug 5

  Armata’s share-price decline drove investment markdowns and a net loss despite growing IST product sales.

• 8-KLeadership change

  Filed May 18

  Small and DiPaolo leave the board to focus on Syndeio BioSciences; Josephine Linden joins as an independent director.

• 10-QQ1 FY2026

  Filed May 6

  XACDURO growth offset declining GSK royalties, but commercial spending weighed on operating income while Armata valuation gains drove GAAP profit.

  • Revenue$98.0MYoY +10.6%
  • Net income$186.6Mvs −$46.6M year ago

• 8-KEarnings

  Filed May 6

  Armata Pharmaceuticals’ share-price gains drove the swing to profit; product sales growth offset lower royalty revenue.

• 8-KShareholder voteExecutive pay

  Filed May 4

  Stockholders approved the 2026 Equity Incentive Plan and backed executive compensation in an advisory vote.

• 8-KPositiveEarningsNew guidance

  Filed Feb 25

  Armata share-price gains drove the profit surge; newly approved NUZOLVENCE is slated for H2 2026 commercialization.

• 10-KFY2025Positive

  Filed Feb 25

  GIAPREZA and XACDURO lifted product sales, but at-cost Zai Lab supply limited margins; Armata investment gains drove GAAP earnings.

  • Revenue$411.3MYoY +14.7%
  • Net income$271.2MYoY +1059.2%

Coverage: 10-K and 8-K filings filed since Feb 25, 2026; 10-Q since May 6, 2026.

Request longer coverage